These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30038419)

  • 1. Mapping the genetic basis of breast microcalcifications and their role in metastasis.
    Rizwan A; Paidi SK; Zheng C; Cheng M; Barman I; Glunde K
    Sci Rep; 2018 Jul; 8(1):11067. PubMed ID: 30038419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435.
    Shevde LA; Samant RS; Paik JC; Metge BJ; Chambers AF; Casey G; Frost AR; Welch DR
    Clin Exp Metastasis; 2006; 23(2):123-33. PubMed ID: 16830223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteopontin knockdown inhibits αv,β3 integrin-induced cell migration and invasion and promotes apoptosis of breast cancer cells by inducing autophagy and inactivating the PI3K/Akt/mTOR pathway.
    Zhang H; Guo M; Chen JH; Wang Z; Du XF; Liu PX; Li WH
    Cell Physiol Biochem; 2014; 33(4):991-1002. PubMed ID: 24714122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor.
    Yang L; Zhao W; Zuo WS; Wei L; Song XR; Wang XW; Zheng G; Zheng MZ
    Chin Med J (Engl); 2012 Jan; 125(2):293-9. PubMed ID: 22340562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis.
    Beausoleil MS; Schulze EB; Goodale D; Postenka CO; Allan AL
    BMC Cancer; 2011 Jan; 11():25. PubMed ID: 21247495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretory pathway Ca
    Dang D; Prasad H; Rao R
    Mol Carcinog; 2017 Nov; 56(11):2474-2485. PubMed ID: 28618103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microcalcifications in breast cancer: an active phenomenon mediated by epithelial cells with mesenchymal characteristics.
    Scimeca M; Giannini E; Antonacci C; Pistolese CA; Spagnoli LG; Bonanno E
    BMC Cancer; 2014 Apr; 14():286. PubMed ID: 24758513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells.
    Hahnel A; Wichmann H; Kappler M; Kotzsch M; Vordermark D; Taubert H; Bache M
    Radiat Oncol; 2010 Sep; 5():82. PubMed ID: 20849637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1.
    Hedley BD; Welch DR; Allan AL; Al-Katib W; Dales DW; Postenka CO; Casey G; Macdonald IC; Chambers AF
    Int J Cancer; 2008 Aug; 123(3):526-34. PubMed ID: 18470911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditional Knockdown of Osteopontin Inhibits Breast Cancer Skeletal Metastasis.
    Kovacheva M; Zepp M; Schraad M; Berger S; Berger MR
    Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31590218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models.
    Mutrie JC; Chambers AF; Tuck AB
    Cancer Biol Ther; 2011 Oct; 12(8):680-90. PubMed ID: 21795853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts.
    Suzuki M; Mose E; Galloy C; Tarin D
    Am J Pathol; 2007 Aug; 171(2):682-92. PubMed ID: 17620367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 suppresses osteopontin-mediated breast cancer.
    El-Tanani MK; Campbell FC; Crowe P; Erwin P; Harkin DP; Pharoah P; Ponder B; Rudland PS
    J Biol Chem; 2006 Sep; 281(36):26587-601. PubMed ID: 16807234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells.
    Yang L; Wei L; Zhao W; Wang X; Zheng G; Zheng M; Song X; Zuo W
    Mol Med Rep; 2012 Feb; 5(2):373-6. PubMed ID: 22143930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis.
    Raja R; Kale S; Thorat D; Soundararajan G; Lohite K; Mane A; Karnik S; Kundu GC
    Oncogene; 2014 Apr; 33(16):2053-64. PubMed ID: 23728336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-α9β1 integrin-mediated signaling induces breast cancer growth and lymphatic metastasis via the recruitment of cancer-associated fibroblasts.
    Ota D; Kanayama M; Matsui Y; Ito K; Maeda N; Kutomi G; Hirata K; Torigoe T; Sato N; Takaoka A; Chambers AF; Morimoto J; Uede T
    J Mol Med (Berl); 2014 Dec; 92(12):1271-81. PubMed ID: 25099519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms.
    Schulze EB; Hedley BD; Goodale D; Postenka CO; Al-Katib W; Tuck AB; Chambers AF; Allan AL
    Breast Cancer Res Treat; 2008 Nov; 112(2):243-54. PubMed ID: 18097747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype.
    Li NY; Weber CE; Mi Z; Wai PY; Cuevas BD; Kuo PC
    J Am Coll Surg; 2013 Jul; 217(1):17-26; discussion 26. PubMed ID: 23619316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fam20C Regulates Bone Resorption and Breast Cancer Bone Metastasis through Osteopontin and BMP4.
    Zuo H; Yang D; Wan Y
    Cancer Res; 2021 Oct; 81(20):5242-5254. PubMed ID: 34433585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of osteopontin attenuates breast tumour progression in vivo.
    Chakraborty G; Jain S; Patil TV; Kundu GC
    J Cell Mol Med; 2008 Dec; 12(6A):2305-18. PubMed ID: 18266970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.